Estonia Infection Control Market - Forecasts from 2020 to 2025
Estonia infection control market is projected to reach US$6.681 million by 2025. Due to a considerably greater gap between socioeconomic groups of Estonia when compared to the European Union (EU) the government of Estonia in 2017 provided more sustainable funding to its highly centralized health insurance system, which is a single entity, with the potential objective to reduce fragmentation and increase coordination. Despite a visible improvement with regards to life expectancy since 2000 that has increased more in Estonia than in any other EU country, nearly half of all deaths in Estonia result from behavioral risks, above the EU average of 39%. As of 2017, Estonia had the third-highest adult obesity rates after Malta and Latvia with a significant increase in childhood obesity. Albeit, the rate of smoking and drinking has declined it has remained significantly higher than that of the EU averages. Further, the expenditure on health care per person borne by Estonia is approximately half the EU average which is to the tune of EUR 1, 559 and is at an equivalent to 6.4% of GDP.
The health insurance system that is single entity accounts for three-quarters of health spending whereas 23.6% is from out-of-pocket payments. Since the country relies on general practitioners and outpatient specialists to provide care, most of the spending covers outpatient or ambulatory services. Even though the health status of Estonian people is now nearing the EU average, mainly due to fewer deaths from ischemic heart disease and strokes, Self-reported unmet health care needs are the highest in the EU and affect individuals across various income groups. Further, in 2016, ischaemic heart disease represented one-fifth of all deaths in Estonia (3 120 deaths). To this end, it may be noted that the mortality rate from ischaemic heart disease in Estonia (252 deaths per 100 000 population) is more than twice the EU average of 118.8. Lung cancer is the most frequent cause of death by cancer among Estonians and the third-highest cause of death overall at 51 deaths per 100 000 population. Hospitals in Estonia are mostly owned by the state, local governments or public legal bodies, while primary care centers, pharmacies and outpatient clinics (if not part of a hospital) are privately owned. Thus, this is also another region where the state bears a substantial expenditure towards the health care along with the private sector. Estonia’s two largest hospitals, located in Tallinn and Tartu, account for 50% of specialist services.
Further, In Estonia, 12 patients per 100 000 population died from a heart attack and 17 died from a stroke within 30 days from being admitted to hospital. This is higher than the EU average [Source: OECD/European Observatory on Health Systems and Policies (2019), Estonia: Country Health Profile 2019, State of Health in the EU]. Therefore, there have been conscientious efforts from the government to provide various healthcare offerings along with a relative increase in number of private participants. Further, there is still is a decent portion of the population who suffer from major diseases that require inpatient care. Furthermore, there are also surgeries like cataracts whereby the maximum percentage of patients leave by the same day making room for more operations to take place. Therefore, with the prevalence of diseases, the involvement of the government and inclusion of private players to uphold the wellbeing of the patients as well as high patient turnover as exemplified by patients of cataract operations the need for following inception prevention protocol by the healthcare segment of the country is of paramount importance. This need will drive the demand for infection prevention products during the forecast thereby throttling the growth of the Infection Control Market of Estonia during the forecast period as well.
Segmentation
The health insurance system that is single entity accounts for three-quarters of health spending whereas 23.6% is from out-of-pocket payments. Since the country relies on general practitioners and outpatient specialists to provide care, most of the spending covers outpatient or ambulatory services. Even though the health status of Estonian people is now nearing the EU average, mainly due to fewer deaths from ischemic heart disease and strokes, Self-reported unmet health care needs are the highest in the EU and affect individuals across various income groups. Further, in 2016, ischaemic heart disease represented one-fifth of all deaths in Estonia (3 120 deaths). To this end, it may be noted that the mortality rate from ischaemic heart disease in Estonia (252 deaths per 100 000 population) is more than twice the EU average of 118.8. Lung cancer is the most frequent cause of death by cancer among Estonians and the third-highest cause of death overall at 51 deaths per 100 000 population. Hospitals in Estonia are mostly owned by the state, local governments or public legal bodies, while primary care centers, pharmacies and outpatient clinics (if not part of a hospital) are privately owned. Thus, this is also another region where the state bears a substantial expenditure towards the health care along with the private sector. Estonia’s two largest hospitals, located in Tallinn and Tartu, account for 50% of specialist services.
Further, In Estonia, 12 patients per 100 000 population died from a heart attack and 17 died from a stroke within 30 days from being admitted to hospital. This is higher than the EU average [Source: OECD/European Observatory on Health Systems and Policies (2019), Estonia: Country Health Profile 2019, State of Health in the EU]. Therefore, there have been conscientious efforts from the government to provide various healthcare offerings along with a relative increase in number of private participants. Further, there is still is a decent portion of the population who suffer from major diseases that require inpatient care. Furthermore, there are also surgeries like cataracts whereby the maximum percentage of patients leave by the same day making room for more operations to take place. Therefore, with the prevalence of diseases, the involvement of the government and inclusion of private players to uphold the wellbeing of the patients as well as high patient turnover as exemplified by patients of cataract operations the need for following inception prevention protocol by the healthcare segment of the country is of paramount importance. This need will drive the demand for infection prevention products during the forecast thereby throttling the growth of the Infection Control Market of Estonia during the forecast period as well.
Segmentation
- By Product
- Disinfectants
- Sterilization
- Low-Temperature Sterilization
- Heat Sterilization
- Contract Sterilization
- By End User Industry
- Healthcare
- Food and Beverage
- Chemical
1. INTRODUCTION
1.1. Market Definition
1.2. Market Segmentation
2. RESEARCH METHODOLOGY
2.1. Research Data
2.2. Assumptions
3. EXECUTIVE SUMMARY
3.1. Research Highlights
4. MARKET DYNAMICS
4.1. Market Drivers
4.2. Market Restraints
4.3. Porters Five Forces Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Power of Buyers
4.3.3. The threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis
5. ESTONIA INFECTION CONTROL MARKET, BY PRODUCT
5.1. Introduction
5.2. Disinfectants
5.3. Sterilization
5.3.1. Low-Temperature Sterilization
5.3.2. Heat Sterilization
5.3.3. Contract Sterilization
6. ESTONIA INFECTION CONTROL MARKET, BY END USER INDUSTRY
6.1. Introduction
6.2. Healthcare
6.3. Food and Beverage
6.4. Chemical
7. COMPETITIVE ENVIRONMENT AND ANALYSIS
7.1. Major Players and Strategy Analysis
7.2. Emerging Players and Market Lucrativeness
7.3. Mergers, Acquisitions, Agreements, and Collaborations
7.4. Vendor Competitiveness Matrix
8. COMPANY PROFILES
8.1. 3M
8.2. ASP
8.3. Cardinal Health
8.4. Merck Serono O? (Merck KGaA)
8.5. Tuttnauer
8.6. List is not Exhaustive*
1.1. Market Definition
1.2. Market Segmentation
2. RESEARCH METHODOLOGY
2.1. Research Data
2.2. Assumptions
3. EXECUTIVE SUMMARY
3.1. Research Highlights
4. MARKET DYNAMICS
4.1. Market Drivers
4.2. Market Restraints
4.3. Porters Five Forces Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Power of Buyers
4.3.3. The threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis
5. ESTONIA INFECTION CONTROL MARKET, BY PRODUCT
5.1. Introduction
5.2. Disinfectants
5.3. Sterilization
5.3.1. Low-Temperature Sterilization
5.3.2. Heat Sterilization
5.3.3. Contract Sterilization
6. ESTONIA INFECTION CONTROL MARKET, BY END USER INDUSTRY
6.1. Introduction
6.2. Healthcare
6.3. Food and Beverage
6.4. Chemical
7. COMPETITIVE ENVIRONMENT AND ANALYSIS
7.1. Major Players and Strategy Analysis
7.2. Emerging Players and Market Lucrativeness
7.3. Mergers, Acquisitions, Agreements, and Collaborations
7.4. Vendor Competitiveness Matrix
8. COMPANY PROFILES
8.1. 3M
8.2. ASP
8.3. Cardinal Health
8.4. Merck Serono O? (Merck KGaA)
8.5. Tuttnauer
8.6. List is not Exhaustive*
